Lupin and Salix Pharmaceuticals Update by Epic Research

Lupin and Salix Pharmaceuticals, Inc. (Salix) have entered into a definitive distribution agreement under which Salix has granted Lupin the exclusive right to market, distribute and sell certain Salix products in Canada. This includes immediate rights to distribute Zaxine (rifaximin) 550 mg tablets for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age or older, and Relistor Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.

Real Time News & Trading Trends Keep Liking Epic Research Private Limited

Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+

For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co